Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

Completed · Not applicable

Conditions studied: Healthy

In brief

The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.

Key facts

Study ID

NCT01431300

Run by

Duke University

People needed

30

Starts

2011-08-01

Expected to finish

2013-07-01

Last updated by the study team

2013-12-10

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• healthy male or female subjects between 18-45 years of age

You may not qualify if…

• Pregnant and lactating females
• known renal impairment
• allergy to gadolinium-based contrast
• metallic implanted devices
• claustrophobia.

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.